TLR2 Agonist Compounds for Respiratory Infection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for respiratory infections, particularly those caused by viruses, are inadequate due to limitations in vaccine effectiveness, timing, and the lack of protection against pandemics, and existing therapies fail to prevent exacerbations of conditions like asthma and COPD.
Innovation Solution
Development of Toll-Like Receptor 2 (TLR2) agonist compounds and their compositions that demonstrate improved stability and efficacy in treating and preventing respiratory diseases associated with viral or bacterial infections by stimulating the innate immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vaccines are administered to prevent respiratory infections, then protection against specific viral strains is improved, but protection is inadequate due to lag phase between inoculation and antibody formation, and does not cover pandemics or all strains
Solution Approach 1:
The TLR2 agonist compounds activate the innate immune system in advance of pathogen exposure, inducing an interferon-mediated antiviral state that provides immediate protection without the lag phase associated with adaptive immune response or traditional vaccination
2Adaptability or versatility
If seasonal vaccinations are reformulated and re-administered to maintain protection, then coverage of emerging strains is improved, but the complexity and frequency of administration increases
Solution Approach 1:
The TLR2 agonist compounds provide universal protection against multiple viral strains and types through a common mechanism of innate immune activation, eliminating the need for strain-specific vaccine formulations and re-administration programs
3Reliability
If TLR2 agonist compounds are developed to stimulate innate immune response, then protection against respiratory infections is improved, but stability of the compounds may be compromised
Solution Approach 1:
The patent modifies chemical parameters of the TLR2 agonist compounds, including the hydrophobic moiety structure, linker length and composition, and PEG chain length, to optimize the balance between biological activity and solution stability
Solution Approach 2:
The compounds utilize composite structures combining hydrophobic moieties (for TLR2 binding affinity), flexible linkers (for molecular conformation), and hydrophilic PEG chains (for solubility and stability), creating molecules that achieve both high efficacy and improved solution stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TLR2 agonist compounds effectively raise an innate immune response, providing enhanced protection against respiratory infections and improving the ability to control respiratory diseases during viral infections, with improved stability and efficacy compared to existing compounds.
Implementation Method 1
TLR2 agonist compounds effectively raise an innate immune response, providing enhanced protection against respiratory infections
Data Source
AI summary
The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.